

Edgar Filing: PRO PHARMACEUTICALS INC - Form 8-K

PRO PHARMACEUTICALS INC  
Form 8-K  
January 16, 2007

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

-----  
FORM 8-K  
-----

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

January 16, 2007  
Date of Report (Date of earliest event reported)

-----  
PRO-PHARMACEUTICALS, INC.  
(Exact Name of Registrant as Specified in Charter)

-----  
NEVADA  
(State or Other Jurisdiction  
of Incorporation)

000-32877  
(Commission File Number)

04-3562325  
(IRS Employer  
Identification No.)

7 WELLS AVENUE  
NEWTON, MASSACHUSETTS  
02459  
(Address of Principal Executive Offices) (Zip Code)

(617) 559-0033  
(Registrant's telephone number, including area code)

-----  
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

=====  
Item 5.02. Departure of Directors or Principal Officers; Election of Directors;

Edgar Filing: PRO PHARMACEUTICALS INC - Form 8-K

Appointment of Principal Officers.

On January 16, 2007, we received a letter from Burton C. Firtel, one of our directors, notifying us of Mr. Firtel's resignation from the Board of Directors of Pro-Pharmaceuticals, Inc. effective immediately. A copy of Mr. Firtel's resignation letter is filed herewith as Exhibit 17.1.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

17.1 Letter of Burton C. Firtel to David Platt, Chief Executive Officer of Pro-Pharmaceuticals, Inc., dated January 11, 2007

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PRO-PHARMACEUTICALS, INC.

Date: January 16, 2007

By: /s/ David Platt

---

David Platt  
Chief Executive Officer

---

EXHIBIT INDEX

Exhibit Number	Exhibit
17.1	Letter of Burton C. Firtel to David Platt, Chief Executive Officer of Pro-Pharmaceuticals, Inc., dated January 11, 2007